# A Study Comparing Oxymetazoline 1% Cream to RHOFADE

> **NCT05148689** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Oxymetazoline hydrochloride Cream, 1%
- **DRUG:** Rhofade™ (oxymetazoline) cream, 1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05148689
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-23
- **Primary completion:** 2019-03-21
- **Final completion:** 2019-05-31
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148689, "A Study Comparing Oxymetazoline 1% Cream to RHOFADE". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05148689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*